<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Schaafsma E</submitter><funding>NIAID NIH HHS</funding><funding>NCI NIH HHS</funding><funding>U.S. Department of Health &amp;amp; Human Services | National Institutes of Health</funding><funding>Cancer Prevention and Research Institute of Texas</funding><pagination>422-432</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8329209</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>125(3)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The function of major histocompatibility complex (MHC) molecules is to bind peptide fragments derived from genomic mutations or pathogens and display them on the cell surface for recognition by cognate T cells to initiate an immune response.&lt;h4>Methods&lt;/h4>In this study, we provide a comprehensive investigation of HLA gene expression in a pan-cancer manner involving 33 cancer types. We utilised gene expression data from several databases and immune checkpoint blockade-treated patient cohorts.&lt;h4>Results&lt;/h4>We show that MHC expression varies strongly among cancer types and is associated with several genomic and immunological features. While immune cell infiltration was generally higher in tumours with higher HLA gene expression, CD4+ T cells showed significantly differen</pubmed_abstract><journal>British journal of cancer</journal><pubmed_title>Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy.</pubmed_title><pmcid>PMC8329209</pmcid><funding_grant_id>R21 CA227996</funding_grant_id><funding_grant_id>T32 AI007363</funding_grant_id><funding_grant_id>RR180061</funding_grant_id><funding_grant_id>1R21CA227996</funding_grant_id><pubmed_authors>Schaafsma E</pubmed_authors><pubmed_authors>Cheng C</pubmed_authors><pubmed_authors>Fugle CM</pubmed_authors><pubmed_authors>Wang X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy.</name><description>&lt;h4>Background&lt;/h4>The function of major histocompatibility complex (MHC) molecules is to bind peptide fragments derived from genomic mutations or pathogens and display them on the cell surface for recognition by cognate T cells to initiate an immune response.&lt;h4>Methods&lt;/h4>In this study, we provide a comprehensive investigation of HLA gene expression in a pan-cancer manner involving 33 cancer types. We utilised gene expression data from several databases and immune checkpoint blockade-treated patient cohorts.&lt;h4>Results&lt;/h4>We show that MHC expression varies strongly among cancer types and is associated with several genomic and immunological features. While immune cell infiltration was generally higher in tumours with higher HLA gene expression, CD4+ T cells showed significantly differen</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Aug</publication><modification>2026-05-30T20:53:59.102Z</modification><creation>2025-04-04T10:01:46.707Z</creation></dates><accession>S-EPMC8329209</accession><cross_references><pubmed>33981015</pubmed><doi>10.1038/s41416-021-01400-2</doi></cross_references></HashMap>